Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2011-08-16
2011-08-16
Dahle, Chun (Department: 1644)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S387300, C530S387900, C530S388100, C435S004000, C435S007100, C435S325000, C435S326000
Reexamination Certificate
active
07999077
ABSTRACT:
Antibodies that specifically bind the extracellular domain of IRTA2 are disclosed herein. In one embodiment, these antibodies do not specifically bind IRTA1, IRTA3, IRTA4, or IRTA5. In one example, the antibodies are humanized antibodies. The antibodies can be conjugated to effector molecules, including detectable labels, radionucleotides, toxins and chemotherapeutic agents. The antibodies that specifically bind IRTA2 are of use to detect B cell malignancies, such as hairy cell leukemia and non-Hodgkin's lymphoma. These antibodies that specifically bind IRTA2 are also of use to treat B cell malignancies that express IRTA2, such as hairy cell leukemia and non-Hodgkin's lymphoma.
REFERENCES:
patent: 4892827 (1990-01-01), Pastan et al.
patent: 5530101 (1996-06-01), Queen et al.
patent: 5602095 (1997-02-01), Pastan et al.
patent: 5608039 (1997-03-01), Pastan et al.
patent: WO 01/38490 (2001-05-01), None
patent: WO 03/024392 (2003-03-01), None
patent: WO 03/083076 (2003-10-01), None
patent: WO 03/089624 (2003-10-01), None
patent: WO 2004/045516 (2004-06-01), None
patent: WO 2005/063299 (2005-07-01), None
SEQ ID No. 13 alingment with IRTA2 from WO 01/38490. p. 1. generated on Jun. 16, 2009.
Rudikoff et al. PNAS 1982 vol. 79, pp. 1979-1983.
Rader et al. PNAS. 1998. 95:8910-8915.
Pai et al. PNAS 1991. 88:3358-62.
Kondo et al. JBC 1988. 263:9470-9475.
Pastan et al. Biochim. Biophys. Acta. 1997. 1333:C1-C6.
Coleman et al. Research in Immunology, 1994; 145(1): 33-36.
“Anti-IRTA2 Polyclonal Antibody,” Product Sheet, cites Hatzivassiliou et al.,Immunity14:272-289, 2001.
Aurias and Dutrillaux, “Probably involvement in immunoglobulin superfamily genes in most recurrent chromosomal rearrangements from ataxia telangiectasia,”Human Genetics72(3):210-4, Mar. 1986Abstract Only.
Dalton et al., “Multiple Myeloma,”Hematologyp. 157-177, 2001.
Davis et al., “Fc receptor homologs: newest members of a remarkably diverse Fc receptor gene family,”Immunological Review190:123-136, 2002.
Davis et al., “Identification of a family of Fc receptor homologs with preferential B cell expression,”PNAS98(17):9772-9777, Aug. 14, 2001.
Falini et al., “Expression of the IRTA1 receptor identifies intraepithelial and subepithelial marginal zone B cells of the mucosa-associated lymphoid tissue (MALT),”Blood102(10):3684-3692, Nov. 15, 2003.
Gozzetti et al., “Identification of Novel Cryptic Translocations InvolvingIGHin B-Cell Non-Hodgkin's Lymphomas,”Cancer research62:5523-5527, Oct. 1, 2002.
Hatzivassiliou et al., “IRTA1 and IRTA2, novel immunoglobulin superfamily receptor expressed in B cells and involved in chromosome 1q21 abnormalities in B cell malignancy,”Immunity14(3):277-289, Mar. 2001.
Ise et al., “Immunoglobulin Superfamily Receptor Translocation Associated 2 Protein on Lymphoma Cell Lines and Hairy Cell Leukemia Cells Detected by Novel Monoclonal Antibodies,”Clinical Cancer Research11:87-96, Jan. 1, 2005.
Ise et al., “ITRA2 Protein on Lymphoma Cell Lines and Hairy Cell Leukemia Cells Detected by Novel Monoclonal Antibodies,”Blood104(11):313A, Nov. 2004Abstract Only.
Itoyama, et al., “Molecular cytogenetic analysis of genomic instability at the 1q12-22 chromosomal site in B-cell non-Hodgkin lymphoma,”Genes, Chromosomes and Cancer35(4):318-328, published online Jul. 23, 2002Abstract Only.
Miller et al., “IRTAs: a new family of immunoglobulinlike receptors differentially expressed in B cells,”Blood99(8):2662-2669, Apr. 15, 2002.
Nakayama et al., “BXMAS1 Identifies a Cluster of Homologous Genes Differentially Expressed in B Cells,”Biochemical and Biophysical Research Communications285:830-837, 2001.
Pileri et al., “Indolent lymphoma: the pathologist's viewpoint,”Annals of Oncology15:12-18, 2004.
Accession No. NM 031281, Davis et al., http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val+14550413, printed Aug. 3, 2004.
Besa, et al., “Hairy Cell Leukemia,”eMedicinefound at http://emedicine.com/med/topic937.htm printed Aug. 2, 2004.
Gentaur Molecular Products bvba Immune System, found at http://www.gentaur.com/acatalog/GENTAUR—Immune—System—192.html, printed Aug. 3, 2004.
“Hairy Cell Leukemia,”National Cancer Institutefound at http://www.imsdd.meb.uni-bonn.de/cancer.gov/CDR0000062926.html printed on Aug. 2, 2004.
“Immunoglobulin superfamily receptor translocation associated 2 IR polyclonal antibody,”Orbigen, Inc. found at http://www.orbigen.com/commerce/catalog/product.jsp?product—id+1846, printed Aug. 3, 2004.
“Homo sapiensgene IRTA2 encoding immunoglobulin superfamily receptor translocation associated 2,” found at http://www.ncbi.nlm.nih.gov/IEB/Research/Acembly/av.cgi?db+human&c+gene&a=fiche&... printed Aug. 3, 2004.
“Immunoglobulin Superfamily Receptor Translocation-Associated Gene2,”OMIMfound at http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=OMIM&dopt=Detailed... printed Aug. 3, 2004.
Ise Tomoko
Nagata Satoshi
Pastan Ira
Xiang Laiman
Dahle Chun
Klarquist & Sparkman, LLP
The United States of America as represented by the Secretary of
LandOfFree
IRTA2 antibodies and methods of use does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with IRTA2 antibodies and methods of use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and IRTA2 antibodies and methods of use will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2699677